NEW YORK – DNA Script said on Tuesday that it has completed its Series C financing with $200 million in new capital, building upon a $165 million dollar tranche announced last year.
The company, which has now raised $315 million since its founding in 2014, will use the proceeds to continue developing its Syntax enzymatic DNA synthesis platform. Syntax is a benchtop instrument that enables on-demand DNA printing without the need for toxic chemicals or waiting for genetic material to arrive from third-party vendors.
Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the latest tranche, as did Healthcor Management, eureKARE, and Irving Investors, joining Coatue Management, Catalio Capital Management, Fidelity Management & Research Company, Columbia Threadneedle Investments, Casdin Capital, and other investors who participated in the first closing.
DNA Script received CE marking for Syntax late last year, clearing the path for the device's commercial sales in Europe.
The company plans to commercially launch Syntax in both the US and Europe early this year.
"Syntax is the first step toward creating a new paradigm for DNA and RNA synthesis," DNA Script CEO and cofounder Thomas Ybert said in a statement. "With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our largest challenges and advance human health."